Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2020-08-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
第七届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board regarding the approval of the company's 2020 semi-annual report and its summary. It states that the supervisory board has reviewed and approved the 2020 half-year report, confirming its compliance with laws and regulations. However, the document itself does not contain the full semi-annual report or detailed financial data; instead, it references where the full report and summary can be found (on a website and in a newspaper). The document length is short (740 characters), and it serves as an announcement of the approval and availability of the interim report rather than the report itself. According to the 'Menu vs Meal' rule, such a document should be classified as a Regulatory Filing (RNS) because it announces the report but does not contain the substantive financial data or analysis of the interim report itself.
2020-08-25 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees and the use of company funds by controlling shareholders and related parties. It references regulatory notices from the China Securities Regulatory Commission and discusses compliance with laws and internal management systems. The document is relatively short (840 characters) and focuses on governance and compliance matters rather than presenting financial data or audit results. It does not contain financial statements or detailed financial analysis, nor is it an announcement of a report publication. The content aligns with a governance-related disclosure rather than an audit report or financial report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2020-08-25 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled "北京双鹭药业股份有限公司 2020 年半年度报告摘要" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2020 Semi-Annual Report Summary." It contains detailed financial data for the first half of 2020, including revenue, net profit, earnings per share, and other financial indicators. It also discusses business operations, R&D progress, shareholder information, and management commentary on the period's performance. The document is a comprehensive financial report for a period shorter than a full fiscal year (half-year). It is not merely an announcement or a summary directing to a full report but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 4745 characters, which is sufficient to contain detailed financial data and analysis, consistent with an IR filing rather than a brief announcement or summary. H1 2020
2020-08-25 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2020 年半年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2020 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, financial statements, and other comprehensive information for the half-year period ending June 30, 2020. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes financial metrics, business segments, risk factors, and operational analysis typical of an Interim / Quarterly Report. There is no indication that this is an Annual Report (10-K) or a simple announcement of report publication (RPA). Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2020
2020-08-25 Chinese
第七届董事会第十四次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a board meeting resolution announcement from Beijing SL Pharmaceutical Co., Ltd. It reports the approval of the 2020 semi-annual report and its summary by the board of directors. The document states that the full semi-annual report and summary are published elsewhere (in a newspaper and on a website). The document itself does not contain the actual financial statements or substantive financial data, but rather announces the board's approval and references the report's publication. The document length is short (609 characters), consistent with an announcement rather than the full report. Therefore, this is a Declaration of Voting Results & Voting Rights Announcement (DVA), as it officially announces the board's resolution and approval of the semi-annual report.
2020-08-25 Chinese
关于获得富马酸替诺福韦二吡呋酯片药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the receipt of a drug registration certificate for a specific pharmaceutical product. It includes details about the drug, regulatory approval, and potential impact on the company. The document is short (960 characters) and serves as an official announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications related to financial filings. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-20 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.